Loading…
Loading…
EQUITY / NASDAQ · XNCM
ImmuCell Corporation
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗9.75 USD · 0%
Observed: Oct 2, 2026, 8:00 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/02/2026 · 9.75 USD · Volume 5,813
251 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | Prior year | Change |
|---|---|---|---|
| Revenue | 7,186,113 USD | — | — |
| Operating profit | 1,934,934 USD | — | — |
| Net income | 1,834,656 USD | — | — |
| Cash and cash equivalents | 8,860,205 USD | — | — |
| Total liabilities | 15,255,260 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 203/31/2026 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 101/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 8,860,205 USD | — | — | 6,812,637 USD | 3,806,831 USD | 3,806,831 USD | 3,886,198 USD | — |
| Gross profitIncome statement | 2,437,222 USD | 7,094,666 USD | — | 4,657,444 USD | — | 11,445,203 USD | 2,363,098 USD | 8,534,994 USD |
| Net incomeIncome statement | 1,834,656 USD | 3,776,263 USD | — | 1,941,607 USD | — | -1,040,027 USD | -139,748 USD | 1,809,115 USD |
| Operating profitIncome statement | 1,934,934 USD | 3,904,250 USD | — | 1,969,316 USD | — | 1,649,305 USD | 20,075 USD | 1,707,261 USD |
| RevenueIncome statement | 7,186,113 USD | 17,543,408 USD | — | 10,357,295 USD | — | 27,644,174 USD | 5,506,122 USD | 20,018,175 USD |
| Total assetsBalance sheet | 46,629,796 USD | — | — | 44,108,374 USD | 42,532,447 USD | 42,532,447 USD | 45,730,123 USD | — |
| Total equityBalance sheet | 31,374,536 USD | — | 29,135,040 USD | 29,135,040 USD | 27,055,480 USD | 27,055,480 USD | 29,800,841 USD | — |
| Total liabilitiesBalance sheet | 15,255,260 USD | — | — | 14,973,334 USD | 15,476,967 USD | 15,476,967 USD | 15,929,282 USD | — |
| Capital expendituresCash flow statement | — | 911,169 USD | — | 177,230 USD | — | 1,250,439 USD | — | 1,078,133 USD |
| Financing cash flowCash flow statement | — | -637,559 USD | — | -399,995 USD | — | -1,212,386 USD | — | -817,784 USD |
| Investing cash flowCash flow statement | — | -901,169 USD | — | -167,230 USD | — | -1,214,307 USD | — | -1,047,001 USD |
| Operating cash flowCash flow statement | — | 6,592,102 USD | — | 3,573,031 USD | — | 2,475,292 USD | — | 1,992,751 USD |
| Report source | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 05/14/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 03/30/2026 | Open report ↗ Published: 11/13/2025 | Open report ↗ Published: 11/13/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.